DiaSorin S.p.A. is an Italy-based medical diagnostics company that develops, manufactures and markets in vitro diagnostic technologies and laboratory testing solutions. The company focuses primarily on immunodiagnostics and molecular diagnostics, supporting the detection and monitoring of infectious diseases, endocrine and metabolic conditions, autoimmune disorders, and other clinical conditions.
Its product portfolio includes automated immunoassay systems, reagents, molecular testing platforms and specialized laboratory assays. DiaSorin’s LIAISON family of analyzers and related assays is used by clinical laboratories and healthcare providers for applications such as infectious disease screening, allergy testing, endocrinology, oncology and gastrointestinal diagnostics. The company also offers molecular testing solutions for respiratory and other infectious diseases.
Founded in 1968, DiaSorin has expanded from its Italian base into an international diagnostics group. It serves hospitals, clinical laboratories, blood banks and other healthcare organizations across Europe, North America, Asia and additional global markets through direct operations and distribution partners. The company is headquartered in Saluggia, Italy, and its shares trade on the Euronext Milan exchange under the ticker DIA; its ordinary shares are also represented in the U.S. over-the-counter market under the symbol DSRLF.
AI Generated. May Contain Errors.
